Xcout Intel
Kamada
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Subscribe to see Kamada’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Kamada at a glance
Kamada is a biotech, pharmaceuticals company headquartered in Rehovot, Israel, founded in 1990. It is publicly listed (KMDA) with a market capitalisation of $404.9M. Xcout tracks 22 named people at Kamada, including Amir London (Chief Executive Officer).
Kamada leadership
- Amir LondonChief Executive Officer
- Eran NirChief Operating Officer
- Chaime OrlevChief Financial Officer
- David TsurCo-Founder & Independent Deputy Chairman of the Board
- Ishay DavidiMember of our board of directors
- Boris GorelikVice President of Business Development & Strategic Programs
16 more named people on record for Kamada, with roles, board committees and tenure — see the full roster →
Kamada competitors
A few of Kamada's closest competitors — see the full list of competitors and alternatives →
Rekah Pharmaceutical Industry Ltd., established in 1941 and headquartered in Holon, Israel, specializes in the production, marketing, distribution, and sale of a broad spectrum of healthcare items across Israel. The company's offerings include both prescription and over-the-counter medicines, dermo-cosmetic products, vitamins, and nutritional supplements. Its extensive portfolio comprises approximately 280 distinct pharmaceutical drugs used in various medical sectors. These encompass steroid tablets, antibiotics (such as penicillin and cephalosporin), eye drops and ointments for allergies, infections, and dryness, baby products, and dermatological treatments.
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Biomedica Management Corp is a pharmaceutical company that specializes in the commercialization, distribution, and in-licensing of rare disease and innovative therapies in emerging and underserved markets. It provides biopharmaceutical partners with comprehensive services including market access strategies, regulatory navigation, and reimbursement solutions to expand patient access to breakthrough treatments.
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.
Viatris is a global healthcare company that develops, manufactures, and supplies a wide range of pharmaceutical products, including generics, established brands, and innovative medicines. The company serves patients worldwide across various therapeutic areas to address significant unmet medical needs.
Get Kamada's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Kamada in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access